

Invitation to presentation of Nanexa's Q3 report 2024

Nanexa AB (publ) will publish its report for the third quarter of 2024 on November 7, 2024 and invites to a comment of the report.

The live commentary with CEO David Westberg will take place on November 7 at 10:15 am via Infront Direkt Studios and viewers will have the opportunity to ask questions via chat.

[The report commentary will be available here.](#)

The comment of the report will also be published on Nanexa's website afterwards. The presentation will be held in Swedish.

For additional information, please contact:

David Westberg – CEO, Nanexa AB (publ)
Phone: +46 70 942 83 03
Email: david.westberg@nanexa.se
www.nanexa.com

The company's Certified Adviser is Carnegie Investment Bank AB (publ).

About Nanexa AB (publ)

Nanexa is a pharmaceutical company developing injectable drug products based on the proprietary and innovative drug delivery system PharmaShell® – the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. Nanexa develops its own products and also has collaboration agreements with several pharma companies, among others Novo Nordisk and AstraZeneca.

Nanexa's share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

Attachments

[Invitation to presentation of Nanexa's Q3 report 2024](#)